Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebastine in Diarrhea Predominant IBS
NCT07114055Phase 3Recruiting
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Irritable bowel syndrome with diarrhea (IBS-D) comparing Ebastine Arm with Placebo Arm (2 arms). Primary endpoint: Improvement of diarrhea predominant IBS symptoms (IBS Symptom Severity Score) at 8 weeks. Started Aug 2025; status: recruiting.
02
Drugs
eribulin
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT07114055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114055.